Persistence Innovation To Replenish The
The global Osteoarthritis Market is expected to grow on an enormous note In Upcoming
Years. The industry, in all, is slated to witness an insight-driven revolution, which would, in
turn, open the doors for efficient and effective solutions. These insights would be backed by
digital tech catalysis, right from making use of consumers’ data for understanding their
preferences to getting those customized solutions at the right time. This trend is expected to
take the domains to a new level altogether.
Persistence Market Research (PMR) has published a new research report on
the osteoarthritis treatment market titled “Osteoarthritis Treatment Market: Global
Industry Analysis (2012-2016) and Forecast (2017-2025).” An alarming rise in the
number of osteoarthritis cases is the result of a growing geriatric population worldwide. In
order to cater to the needs of the rapidly increasing geriatric population as well as the
female population – given that osteoarthritis prevails mostly among these groups – the
manufacturers of osteoarthritis drugs are focusing on research and development to be able
to develop better and reliable drugs. As this disease is not treatable, the market is an ever
growing one. In this run, the leading companies are also collaborating with other big
companies in order to use their formulas and production equipment.
Get Sample Copy of this
For instance, in September 2016, Pfizer Inc. completed the acquisition of Medivation, Inc., a
biopharmaceutical company focused on the development and commercialization of
medically innovative therapies to treat serious diseases that have limited treatment options.
In this regard, the company also acquired the commercialization and development rights of
the late stage small molecules anti-infective business, mainly outside the U.S. from
AstraZeneca. Other companies operating in the market are Johnson & Johnson Services